The critical role played by the CD28/CD152-CD80/ CD86 costimulatory molecules in mediating T cell activation and suppression provides attractive targets for therapeutic strategies. CD28 and CD152 share a conserved polyproline motif in the ligand-binding region. Similar proline-rich regions in globular domains preferentially adopt a polyproline type II (PP II ) helical conformation and are involved in transient protein-protein interactions. Interestingly, in the human CD80-CD152 complex, Pro 102 of CD152 restricts the preceding proline to PP II helix in the binding orientation in relation to the shallow binding pocket of CD80. Peptide agents derived from binding sites of receptors that mimic the bioactive conformation have been shown to block receptor-ligand interactions. Contact preferences of the interface amino acids at the protein-protein interaction sites and the propensity of each residue to form PP II helix were integrated in the design of novel peptide agents referred to as CD80 competitive antagonist peptides. Structural and functional studies suggest potential therapeutic value for select CD80 competitive antagonist peptides.The interaction between cell surface costimulatory molecules on antigen-presenting cells and the T cells is critical in modulating cell-cell communication (1). Two structurally and functionally well characterized T cell surface costimulatory molecules are CD28 and the CTLA4 (cytotoxic T lymphocyteassociated antigen)/CD152, both of which bind the same ligands, CD80 (B7-1) and CD86 (B7-2), on the antigen-presenting cells. Whereas signaling via CD28 mediates T cell activation, ligation of CD152 down-regulates T cell proliferation and function (2). Thus, CD80/CD86-CD28/CD152 costimulatory molecules are potential therapeutic targets for modulating T cell responses.Analyses of multiple receptor-ligand interactions suggest that in exposed domains involved in protein-protein interactions that mediate cell signaling, the intermolecular interfaces often present extended shallow clefts on ligand surfaces (3). Hence, molecules whose shapes complement the protein interaction clefts of the ligand surfaces are likely to block receptor binding (4). Previously, several linear peptides with extended polyproline type II (PP II ) 1 conformation have been shown to block ligand-acceptor complexes involved in molecular recognition (5-7). Acceptors are typically large proteins with measurable affinity for specific ligands; the latter can be presented as a small peptide sequence within an exposed loop on the surface of a large protein. Structurally, ligands may exist in extended PP II helical conformation, allowing the backbone atoms of the peptide to form hydrogen bonds with protein acceptor at the interface of the protein-peptide complex (8, 9). Examples of complexes where the ligand is in PP II conformation include the EFPPPPT peptide, which interacts with the VASP (vasodilator-stimulated phosphoprotein) EVH1 (Ena/VASP homology) domain (Protein Data Bank code 1QC6), and the SOS (Son of Sevenless) peptide...